Identify/understand all Alzheimer's-related genes

Meet our funded researcher Giuseppina Tesco, M.D., Ph.D., assistant professor of neuroscience, Alzheimer’s Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine. Early Days Born in Prato, Italy, in the heart of Tuscany, Giuseppina Tesco grew up with an older brother and two very...

Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and...

Alzheimer’s research for many years has been dominated by a focus on Abeta “plaques,” a focus that largely has overlooked the other infamous hallmark of the disease—the tau-based neurofibrillary “tangles.” The research world recently has broadened its scope to include...

Charles Glabe of the University of California at Irvine and our Research Consortium and George Bloom of the University of Virginia have added significantly to the growing evidence of the link between the proteins Abeta and Tau in initiating Alzheimer’s disease.  In a collaboration supported by Cure...

Alzheimer’s disease and Type II diabetes long have been observed to have a clinical connection, with patients with diabetes more than twice as likely as those without the disease to develop Alzheimer’s. But the precise nature of this connection has been a mystery until recently.  Over the last few years,...

The New York Times has a front-page story on the spreading of Taupathology from neuron to neuron, citing papers from the laboratories of Dr.Brad Hyman of Massachusetts General Hospital and Dr. Karen Duff of ColumbiaUniversity. Cure Alzheimer's Fund has been supporting key research alongthese lines over the past...

For the last 27 years, Abeta, a fatty protein that is created in the brain, has been identified as the leading cause of Alzheimer’s disease. As a result, the majority of efforts aimed at developing a cure have targeted Abeta as the enemy. But recent studies have indicated that simply wiping out Abeta in the brain is...

The CAF approach is working. UC San Diego neuroscientist Steve Wagner, a previous recipient of two substantial grants from Cure Alzheimer’s Fund (CAF), has been awarded a $1 million NIH “Blueprint” grant for the fast-track development of a promising Alzheimer’s drug therapy. This is further...

Over the past several decades, it has become increasingly clear that inheritance plays a major role in Alzheimer’s disease.The roughly 25,000 genes in the human genome are composed of DNA packaged into 24 different chromosomes. A gene’s job is either to make proteins or control the activity of other genes. Over...

One of the most important, outstanding genetic questions about Alzheimer's disease is the relationship between the APOE genotype and the risk associated with the disease.  Following a CAF-sponsored meeting with members of our Research Consortium and several other noted researchers, CAF awarded a grant to David...

At Cure Alzheimer's Fund, one of our successful strategies is to fund research that is innovative and based on high-quality science yet deemed risky by traditional funding sources.  Our entrepreneurial approach and ability to provide funds in a quick and efficient manner allows us to fund potentially groundbreaking...

There have been an abundance of preventative measures highlighted in the news about ways to ward off Alzheimer's Disease, everything from curry to crosswords.  And a recent piece in The New York Times suggested many such measures are not valid.  However, while the media can get carried away with some that are...

The discovery of a molecular mechanism linking Alzheimer’s disease and Type 2 Diabetes could lead to exciting new drugs to treat both devastating diseases.  Researchers found that the gene for a protein called SorCS1, which is linked with Type 2 Diabetes, participates directly in the pathogenesis of...

The Alzheimer’s Genome Project™ (AGP) , funded by Cure Alzheimer’s Fund (CAF), is making great scientific progress. This work is providing new understanding of AD pathology and revealing novel genetic information. The more we know about how the disease works, the better the chances are for identifying...

Despite progress in understanding the pathology of Alzheimer's disease, advancements in its diagnosis and treatment are limited.  To address this key need, researchers at the University of Texas Health Science Center at Houston (UTHealth) and the University of Houston (UH) - Ananth Annapragada, Ph.D. and Jason Eriksen,...

It has been five years since the inception of Cure Alzheimer’s Fund and its flagship research project, the “Alzheimer’s Genome Project”, led by the Chair of our Research Consortium, Rudy Tanzi from Massachusetts General Hospital. This bold and unprecedented scientific endeavor sought to identify the entire complement of...